The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
The promise and challenges of immune agonist antibody development in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., & Dustin, M. L. (1999) · Science · doi:10.1126/science.285.5425.221 · Cited by 3,102
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
TUMOR NECROSIS FACTOR RECEPTOR AND Fas SIGNALING MECHANISMS
Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., & Boldin, M. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.331 · Cited by 1,312
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Daëron, M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.203 · Cited by 1,227
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg
Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Hehlgans, T., & Pfeffer, K. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02143.x · Cited by 1,048
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
The molecular architecture of the TNF superfamily
Bodmer, J.-L., Schneider, P., & Tschopp, J. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01995-8 · Cited by 916
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling
Chan, F. K.-M., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2351 · Cited by 856
Integrated molecular analysis of adult T cell leukemia/lymphoma
Kataoka, K., Nagata, Y., Kitanaka, A., Shiraishi, Y., Shimamura, T., Yasunaga, J.-I., Totoki, Y., Chiba, K., Sato-Otsubo, A., Nagae, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3415 · Cited by 794
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
T-cell co-stimulation through B7RP-1 and ICOS
Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G., Zhang, M., Coccia, M. A., Kohno, T., et al. (1999) · Nature · doi:10.1038/45582 · Cited by 777
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Regulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
ICOS is essential for effective T-helper-cell responses
Tafuri, A., Shahinian, A., Bladt, F., Yoshinaga, S. K., Jordana, M., Wakeham, A., Boucher, L.-M., Bouchard, D., Chan, V. S. F., Duncan, G., et al. (2001) · Nature · doi:10.1038/35051113 · Cited by 675
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
Roles of Fc receptors in autoimmunity
Takai, T. (2002) · Nature Reviews Immunology · doi:10.1038/nri856 · Cited by 626
Chung, J. Y., Park, Y. C., Ye, H., & Wu, H. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.4.679 · Cited by 613
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Self-citationThe kinetic-segregation model: TCR triggering and beyond
Davis, S. J., & van der Merwe, P. A. (2006) · Nature Immunology · doi:10.1038/ni1369 · Cited by 561
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 550
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
Eck, M. J., & Sprang, S. R. (1990) · PubMed · doi:10.2210/pdb1tnf/pdb · Cited by 507
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., & Mosyak, L. (2001) · Nature · doi:10.1038/35069118 · Cited by 489
The Structure of Tumor Necrosis Factor-α at 2.6 Å Resolution
Eck, M. J., & Sprang, S. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71533-0 · Cited by 473
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
Harper, K., Balzano, C., Rouvier, E., Mattéi, M. G., Luciani, M. F., & Golstein, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.3.1037 · Cited by 432
The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity
Siegel, R. M., Ka-Ming Chan, F., Chun, H. J., & Lenardo, M. J. (2000) · Nature Immunology · doi:10.1038/82712 · Cited by 431
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
French, R. R., Chan, H. T. C., Tutt, A. L., & Glennie, M. J. (1999) · Nature Medicine · doi:10.1038/8426 · Cited by 426
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1272 · Cited by 424
Fc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Holler, N., Tardivel, A., Kovacsovics-Bankowski, M., Hertig, S., Gaide, O., Martinon, F., Tinel, A., Deperthes, D., Calderara, S., Schulthess, T., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1428-1440.2003 · Cited by 406
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R. K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H., & Fu, Y.-X. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 356
The TNF-receptor-associated factor family
Wajant, H., Henkler, F., & Scheurich, P. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(01)00160-7 · Cited by 353
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
Schwartz, J.-C. D., Zhang, X., Fedorov, A. A., Nathenson, S. G., & Almo, S. C. (2001) · Nature · doi:10.1038/35069112 · Cited by 349
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Rationale for anti-OX40 cancer immunotherapy
Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.-C., Zitvogel, L., & Marabelle, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.021 · Cited by 318
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells
Takeda, I., Ine, S., Killeen, N., Ndhlovu, L. C., Murata, K., Satomi, S., Sugamura, K., & Ishii, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3580 · Cited by 308
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Bispecific antibodies and their applications
Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 288
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., & Krammer, P. H. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.10.3166 · Cited by 278
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
DiLillo, D. J., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.04.016 · Cited by 266
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
TRAIL and its receptors as targets for cancer therapy
Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J., & Okumura, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02181.x · Cited by 254
Nordstrom, J. L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V., Zhang, T., Stavenhagen, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 250
Structure and Dimerization of a Soluble Form of B7-1
Ikemizu, S., Gilbert, R. J. C., Fennelly, J. A., Collins, A. V., Harlos, K., Jones, E. Y., Stuart, D. I., & Davis, S. J. (2000) · Immunity · doi:10.1016/s1074-7613(00)80158-2 · Cited by 249
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
Walczak, H. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008698 · Cited by 242
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
Tolcher, A. W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Di Gravio, D., Huang, B., Gambhire, D., Chen, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1243 · Cited by 236
Antibodies, Fc receptors and cancer
Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 234
Ling, V., Wu, P. W., Finnerty, H. F., Bean, K. M., Spaulding, V., Fouser, L. A., Leonard, J. P., Hunter, S. E., Zollner, R., Thomas, J. L., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1653 · Cited by 230
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al-Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 226
Rationale for anti-GITR cancer immunotherapy
Knee, D. A., Hewes, B., & Brogdon, J. L. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.028 · Cited by 221
Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813175106 · Cited by 218
Faget, J., Bendriss-Vermare, N., Gobert, M., Durand, I., Olive, D., Biota, C., Bachelot, T., Treilleux, I., Goddard-Leon, S., Lavergne, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2409 · Cited by 217
Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., & Allison, J. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019499 · Cited by 213
Vonderheide, R. H., Burg, J. M., Mick, R., Trosko, J. A., Li, D., Shaik, M. N., Tolcher, A. W., & Hamid, O. (2013) · OncoImmunology · doi:10.4161/onci.23033 · Cited by 202
ICOS deficiency in patients with common variable immunodeficiency
Salzer, U., Maul-Pavicic, A., Cunningham-Rundles, C., Urschel, S., Belohradsky, B. H., Litzman, J., Holm, A., Franco, J. L., Plebani, A., Hammarstrom, L., et al. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.07.002 · Cited by 201
Kjærgaard, J., Tanaka, J., Kim, J. A., Rothchild, K. B., Weinberg, A. D., & Shu, S. (2000) · PubMed · Cited by 197
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand
Mages, H. W., Hutloff, A., Heuck, C. J., Büchner, K., Himmelbauer, H., Oliveri, F., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(200004)30:4<1040::aid-immu1040>3.0.co;2-6 · Cited by 193
Lühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021024 · Cited by 193
Eliopoulos, A. G., Davies, C., Knox, P. G., Gallagher, N. J., Afford, S. C., Adams, D. H., & Young, L. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5503-5515.2000 · Cited by 190
Papoff, G., Hausler, P., Eramo, A., Pagano, M. G., Di Leve, G., Signore, A., & Ruberti, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38241 · Cited by 183
Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer
Dollins, C. M., Nair, S., Boczkowski, D., Lee, J., Layzer, J. M., Gilboa, E., & Sullenger, B. A. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.05.016 · Cited by 183
Crystal structure of a soluble CD28-Fab complex
Evans, E. J., Esnouf, R. M., Manso-Sancho, R., Gilbert, R. J. C., James, J. R., Yu, C., Fennelly, J. A., Vowles, C., Hanke, T., Walse, B., et al. (2005) · Nature Immunology · doi:10.1038/ni1170 · Cited by 180
Induction, binding specificity and function of human ICOS
Beier, K. C., Hutloff, A., Dittrich, A., Heuck, C. J., Rauch, A. M., Büchner, K., Ludewig, B., Ochs, H. D., Mages, H. W., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3707::aid-immu3707>3.0.co;2-q · Cited by 180
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 176
White, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4194 · Cited by 171
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Claus, C., Riether, C., Schürch, C., Matter, M. S., Hilmenyuk, T., & Ochsenbein, A. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2791 · Cited by 168
Fisher, T. S., Kamperschroer, C., Oliphant, T., Love, V. A., Lira, P. D., Doyonnas, R., Bergqvist, S., Baxi, S. M., Rohner, A., Shen, A. C., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1237-1 · Cited by 166
B7-H2 Is a Costimulatory Ligand for CD28 in Human
Yao, S., Zhu, Y., Zhu, G., Augustine, M. M., Zheng, L., Goode, D. J., Broadwater, M., Ruff, W. E., Flies, S. J., Xu, H., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.014 · Cited by 165
Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells.
Weiss, A., Manger, B., & Imboden, J. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.3.819 · Cited by 163
Takahashi, N., Matsumoto, K., Saito, H., Nanki, T., Miyasaka, N., Kobata, T., Azuma, M., Lee, S., Mizutani, S., & Morio, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803256 · Cited by 162
Principles of antibody-mediated TNF receptor activation
Wajant, H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.109 · Cited by 161
Shrimali, R. K., Ahmad, S., Verma, V., Zeng, P., Ananth, S., Gaur, P., Gittelman, R. M., Yusko, E., Sanders, C., Robins, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0292 · Cited by 161
Wyzgol, A., Müller, N., Fick, A., Münkel, S., Grigoleit, G. U., Pfizenmaier, K., & Wajant, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802597 · Cited by 159
Yokoyama, W. M., Koning, F., Kehn, P. J., Pereira, G. M. B., Stingl, G., Coligan, J. E., & Shevach, E. M. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.2.369 · Cited by 157
Science gone translational: the OX40 agonist story
Weinberg, A. D., Morris, N. P., Kovacsovics-Bankowski, M., Urba, W. J., & Curti, B. D. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01069.x · Cited by 156
Rüter, J., Antonia, S. J., Burris, H. A., Huhn, R. D., & Vonderheide, R. H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13251 · Cited by 155
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Zamarin, D., Holmgaard, R., Ricca, J. M., Plitt, T., Palese, P., Sharma, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2017) · Nature Communications · doi:10.1038/ncomms14340 · Cited by 152
Bhatia, S., Edidin, M. A., Almo, S. C., & Nathenson, S. G. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.019 · Cited by 150
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 150
Hernandez-Chacon, J. A., Li, Y., Wu, R. C. H., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P., & Radvanyi, L. G. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209e7ec · Cited by 141
Colloidal Drug Formulations Can Explain “Bell-Shaped” Concentration–Response Curves
Owen, S. C., Doak, A. K., Ganesh, A. N., Nedyalkova, L., McLaughlin, C. K., Shoichet, B. K., & Shoichet, M. S. (2014) · ACS Chemical Biology · doi:10.1021/cb4007584 · Cited by 141
Peach, R., Bajorath, J., Naemura, J. R., Leytze, G., Greene, J. L., Aruffo, A. A., & Linsley, P. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.21181 · Cited by 140
Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., & Hattori, K. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt022 · Cited by 136
Di Giacomo, A. M., Calabrò, L., Danielli, R., Fonsatti, E., Bertocci, E., Pesce, I., Fazio, C., Cutaia, O., Giannarelli, D., Miracco, C., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1418-6 · Cited by 135
Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M. H., Northfelt, D., Carson, W. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1508 · Cited by 135
Structural Basis of Signal Transduction in the TNF Receptor Superfamily
Li, J., Yin, Q., & Wu, H. (2013) · Advances in immunology · doi:10.1016/b978-0-12-407707-2.00005-9 · Cited by 133
ICOS Ligation Recruits the p50α PI3K Regulatory Subunit to the Immunological Synapse
Fos, C., Salles, A., Lang, V., Carrette, F., Audebert, S., Pastor, S., Ghiotto, M., Olive, D., Bismuth, G., & Nunès, J. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1969 · Cited by 133
Structural mechanisms of costimulation
Schwartz, J.-C. D., Zhang, X., Nathenson, S. G., & Almo, S. C. (2002) · Nature Immunology · doi:10.1038/ni0502-427 · Cited by 132
Montler, R. D., Bell, R. B., Thalhofer, C., Leidner, R. S., Feng, Z., Fox, B. A., Cheng, A. C., Bui, T. G., Tucker, C., Hoen, H. M., et al. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.16 · Cited by 128
Mahne, A. E., Mauze, S., Joyce-Shaikh, B., Xia, J., Bowman, E. P., Beebe, A. M., Cua, D. J., & JAIN, R. K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0797 · Cited by 127
Influence of immunoglobulin isotype on therapeutic antibody function
Beers, S. A., Glennie, M. J., & White, A. L. (2016) · Blood · doi:10.1182/blood-2015-09-625343 · Cited by 125
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 123
Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martínez‐Forero, I., Perez‐Gracia, J. L., Morales‐Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervás‐Stubbs, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0846-9 · Cited by 115
LICOS, a primordial costimulatory ligand?
Brodie, D. W., Collins, A. V., Iaboni, A., Fennelly, J. A., Sparks, L. M., Xu, X.-N., van der Merwe, P. A., & Davis, S. J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00383-3 · Cited by 111
Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208698109 · Cited by 111
Zhou, P., L’Italien, L., Hodges, D., & Schebye, X. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7365 · Cited by 109
Stone, G. W., Barzee, S., Snarsky, V., Kee, K., Spina, C. A., Yu, X.-F., & Kornbluth, R. S. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1762-1772.2006 · Cited by 107
Zhang, X., Schwartz, J.-C. D., Almo, S. C., & Nathenson, S. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252771499 · Cited by 104
He, L.-Z., Prostak, N., Thomas, L. J., Vitale, L. A., Weidlick, J., Crocker, A., Pilsmaker, C. D., Round, S. M., Tutt, A., Glennie, M. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300409 · Cited by 104
The role of the CD40 pathway in the pathogenesis and treatment of cancer
Eliopoulos, A. G., & Young, L. S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.008 · Cited by 99
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Le, K.-S., Thibult, M., Just-Landi, S., Pastor, S., Gondois‐Rey, F., Granjeaud, S., Broussais, F., Bouabdallah, R., Colisson, R., Caux, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0589 · Cited by 96
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Richman, L. P., & Vonderheide, R. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0152 · Cited by 92
Chodorge, M., Züger, S., Stirnimann, C. U., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.208 · Cited by 87
T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody
Tutt, A. L., O’Brien, L. M., Hussain, A., Crowther, G., French, R. R., & Glennie, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2720 · Cited by 85
Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
Nocentini, G., Ronchetti, S., Petrillo, M. G., & Riccardi, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01753.x · Cited by 83
Activating and inhibitory FcγRs in autoimmune disorders
Nimmerjahn, F. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0052-1 · Cited by 76
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
Metzger, T. C., Long, H., Potluri, S., Pertel, T., Bailey-Bucktrout, S. L., Lin, J. C.-Y., Fu, T., Sharma, P., Allison, J. P., & Feldman, R. M. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3412 · Cited by 71
Wang, J., Zhao, W., Cheng, L., Guo, M., Li, D., Li, X., Tan, Y. J., Ma, S., Li, S., Yang, Y., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000927 · Cited by 70
CD40 ligation for immunotherapy of solid tumours
Todryk, S. M., Tutt, A. L., Green, M. H. A., Smallwood, J. A., Halanek, N., Dalgleish, A. G., & Glennie, M. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00349-5 · Cited by 70
Derer, S., Bauer, P., Lohse, S., Scheel, A. H., Berger, S., Kellner, C., Peipp, M., & Valerius, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202037 · Cited by 68
White, A. L., Dou, L., Chan, H. T. C., Field, V. L., Mockridge, C. I., Moss, K., Williams, E. L., Booth, S. G., French, R. R., Potter, E. A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303204 · Cited by 66
Li, B., Lin, J., VanRoey, M. J., Jure‐Kunkel, M., & Jooss, K. U. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.07.005 · Cited by 63
Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
Gauttier, V., Judor, J., Guen, V. L., Cany, J., Ferry, N., & Conchon, S. (2014) · International Journal of Cancer · doi:10.1002/ijc.28943 · Cited by 62
Activation of the Proapoptotic Death Receptor DR5 by Oligomeric Peptide and Antibody Agonists
Li, B., Russell, S. J., Compaan, D. M., Tótpál, K., Marsters, S. A., Ashkenazi, A., Cochran, A. G., Hymowitz, S. G., & Sidhu, S. S. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.042 · Cited by 62
Sukumar, S., Wilson, D. C., Yu, Y., Wong, J., Naravula, S., Ermakov, G., Riener, R. M., Bhagwat, B., Necheva, A. S., Grein, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1439 · Cited by 62
Morris, N. P., Peters, C., Montler, R. D., Hu, H., Curti, B. D., Urba, W. J., & Weinberg, A. D. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.02.004 · Cited by 61
Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Hussain, K., Hargreaves, C. E., Roghanian, A., Oldham, R. J., Chan, H. T. C., Mockridge, C. I., Chowdhury, F., Frendéus, B., Harper, K., Strefford, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593061 · Cited by 55
The TNF ligand superfamily and its relevance for human diseases.
Gruss, H. J., & Dower, S. (1995) · PubMed · Cited by 54
Leyland, R., Watkins, A., Mulgrew, K. A., Holoweckyj, N., Bamber, L., Tigue, N. J., Offer, E., Andrews, J. L., Li, Y., Mullins, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2000 · Cited by 52
Zhou, Z., Song, X., Berezov, A., Zhang, G., Li, Y., Zhang, H., Murali, R., Li, B., & Greene, M. I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711350105 · Cited by 51
Anti-CD30 Antibodies for Hodgkin Lymphoma
Foyil, K. V., & Bartlett, N. L. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0053-y · Cited by 49
Durham, N. M., Holoweckyj, N., MacGill, R. S., McGlinchey, K., Leow, C. C., & Robbins, S. H. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0247-0 · Cited by 48
Kalbasi, A. K., Fonsatti, E., Natali, P. G., Altomonte, M., Bertocci, E., Cutaia, O., Calabrò, L., Chiou, M., Tap, W. D., Chmielowski, B., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee73a7 · Cited by 47
FcγR requirements leading to successful immunotherapy
Dahal, L. N., Roghanian, A., Beers, S. A., & Cragg, M. S. (2015) · Immunological Reviews · doi:10.1111/imr.12342 · Cited by 45
Lu, C., Shimaoka, M., Salas, A., & Springer, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3972 · Cited by 44
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Kim, J. M., & Ashkenazi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131625 · Cited by 43
Côté, A. L., Zhang, P., O’Sullivan, J. A., Jacobs, V. L., Clemis, C. R., Sakaguchi, S., Guevara-Patino, J. A., & Turk, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001308 · Cited by 42
Toward experimental assessment of receptor occupancy: TGN1412 revisited
Waibler, Z., Sender, L. Y., Kamp, C., Müller-Berghaus, J., Liedert, B., Schneider, C. K., Löwer, J., & Kalinke, U. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.07.049 · Cited by 40
Bartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302461 · Cited by 40
Tigue, N. J., Bamber, L., Andrews, J. L., Ireland, S., Hair, J. R., Carter, E. P., Sridharan, S., Jovanović, J., Rees, D. G., Springall, J. S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1280645 · Cited by 40
Zhang, D., Armstrong, A. A., Tam, S. H., McCarthy, S. G., Luo, J., Gilliland, G. L., & Chiu, M. L. (2017) · mAbs · doi:10.1080/19420862.2017.1358838 · Cited by 35
Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts
Ara, G., Baher, A., Storm, N. E., Horan, T., Baikalov, C., Brisan, E., Camacho, R., Moore, A., Goldman, H., Kohno, T., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10831 · Cited by 34
Chattopadhyay, K., Bhatia, S., Fiser, A., Almo, S. C., & Nathenson, S. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3920 · Cited by 33
Nocentini, G., Bartoli, A., Ronchetti, S., Giunchi, L., Cupelli, A., Delfino, D. V., Migliorati, G., & Riccardi, C. (2000) · DNA and Cell Biology · doi:10.1089/104454900314474 · Cited by 33
Smulski, C. R., Décossas, M., Chekkat, N., Beyrath, J., Willen, L., Guichard, G., Lorenzetti, R., Rizzi, M., Eibel, H., Schneider, P., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.22 · Cited by 33
Chester, C., Marabelle, A., Houot, R., & Kohrt, H. E. K. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.12.010 · Cited by 28
Gupta, S., Termini, J. M., Rivas, Y., Otero, M. A., Raffa, F. N., Bhat, V. S., Farooq, A., & Stone, G. W. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.081 · Cited by 23
Girard, T., Gaucher, D., Far, M. E., Breton, G., & Sékaly, R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.05.002 · Cited by 19
Miconnet, I., & Pantaleo, G. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.028 · Cited by 19
Despite slow progress, bispecifics generate buzz
Sheridan, C. (2016) · Nature Biotechnology · doi:10.1038/nbt1216-1215 · Cited by 16
Cited by
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Metadata
- Authors
- Mayes, P. A., Hance, K. W., & Hoos, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-06-15
- Volume
- 17
- Issue
- 7
- Pages
- 509-527
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2807748927
- Cited by
- 355
- References
- 194
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.